Fairfield H, Falank C, Avery L, Reagan MR. Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci. 2016;1364:32–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Noll JE, Vandyke K, Hewett DR, Mrozik KM, Bala RJ, Williams SA, et al. PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. J Hematol Oncol. 2015;8:106.

Article  PubMed  PubMed Central  Google Scholar 

Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25:91–101.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Quwaider D, Corchete LA, Misiewicz-Krzeminska I, Sarasquete ME, Perez JJ, Krzeminski P, et al. DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma. J Hematol Oncol. 2017;10:92.

Article  PubMed  PubMed Central  Google Scholar 

Ohguchi H, Harada T, Sagawa M, Kikuchi S, Tai YT, Richardson PG, et al. KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival. Leukemia. 2017;31:2661–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM, et al. Multiple myeloma. Nat Rev Dis Prim. 2024;10:45.

Article  PubMed  Google Scholar 

Niewerth D, Jansen G, Assaraf YG, Zweegman S, Kaspers GJ, Cloos J. Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resist Updat. 2015;18:18–35.

Article  PubMed  Google Scholar 

Chroma K, Skrott Z, Gursky J, Bacovsky J, Moudry P, Buchtova T, et al. A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment. Cell Death Dis. 2022;13:203.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schutkowski M, Bernhardt A, Zhou XZ, Shen M, Reimer U, Rahfeld JU, et al. Role of phosphorylation in determining the backbone dynamics of the serine/threonine-proline motif and Pin1 substrate recognition. Biochemistry. 1998;37:5566–75.

Article  CAS  PubMed  Google Scholar 

Finn G, Lu KP. Phosphorylation-specific prolyl isomerase Pin1 as a new diagnostic and therapeutic target for cancer. Curr Cancer Drug Targets. 2008;8:223–9.

Article  CAS  PubMed  Google Scholar 

Li J, Pu W, Sun HL, Zhou JK, Fan X, Zheng Y, et al. Pin1 impairs microRNA biogenesis by mediating conformation change of XPO5 in hepatocellular carcinoma. Cell Death Differ. 2018;25:1612–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pu W, Li J, Zheng Y, Shen X, Fan X, Zhou JK, et al. Targeting Pin1 by inhibitor API-1 regulates microRNA biogenesis and suppresses hepatocellular carcinoma development. Hepatology. 2018;68:547–60.

Article  CAS  PubMed  Google Scholar 

Shinoda K, Kuboki S, Shimizu H, Ohtsuka M, Kato A, Yoshitomi H, et al. Pin1 facilitates NF-kappaB activation and promotes tumour progression in human hepatocellular carcinoma. Br J Cancer. 2015;113:1323–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wei S, Kozono S, Kats L, Nechama M, Li W, Guarnerio J, et al. Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer. Nat Med. 2015;21:457–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang GL, Liao D, Chen H, Lu Y, Chen L, Li H, et al. The protein level and transcription activity of activating transcription factor 1 is regulated by prolyl isomerase Pin1 in nasopharyngeal carcinoma progression. Cell Death Dis. 2016;7:e2571.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu X, Dong SH, Chen J, Zhou XZ, Chen R, Nair S, et al. Prolyl isomerase PIN1 regulates the stability, transcriptional activity and oncogenic potential of BRD4. Oncogene. 2017;36:5177–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lian X, Lin YM, Kozono S, Herbert MK, Li X, Yuan X, et al. Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways. J Hematol Oncol. 2018;11:73.

Article  PubMed  PubMed Central  Google Scholar 

Fan G, Fan Y, Gupta N, Matsuura I, Liu F, Zhou XZ, et al. Peptidyl-prolyl isomerase Pin1 markedly enhances the oncogenic activity of the rel proteins in the nuclear factor-kappaB family. Cancer Res. 2009;69:4589–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Y, Wu YR, Yang HY, Li XZ, Jie MM, Hu CJ, et al. Prolyl isomerase Pin1: a promoter of cancer and a target for therapy. Cell Death Dis. 2018;9:883.

Article  PubMed  PubMed Central  Google Scholar 

Ryo A, Nakamura M, Wulf G, Liou YC, Lu KP. Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol. 2001;3:793–801.

Article  CAS  PubMed  Google Scholar 

Cheng CW, Leong KW, Tse E. Understanding the role of PIN1 in hepatocellular carcinoma. World J Gastroenterol. 2016;22:9921–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nakamura K, Kosugi I, Lee DY, Hafner A, Sinclair DA, Ryo A, et al. Prolyl isomerase Pin1 regulates neuronal differentiation via beta-catenin. Mol Cell Biol. 2012;32:2966–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shin HR, Islam R, Yoon WJ, Lee T, Cho YD, Bae HS, et al. Pin1-mediated modification prolongs the nuclear retention of beta-catenin in Wnt3a-induced osteoblast differentiation. J Biol Chem. 2016;291:5555–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K, et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res. 2007;67:2982–9.

Agnelli L, Mosca L, Fabris S, Lionetti M, Andronache A, Kwee I, et al. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes Cancer. 2009;48:603–14.

Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010;116:2543–53.

Article  CAS  PubMed  Google Scholar 

Went M, Sud A, Försti A, Halvarsson BM, Weinhold N, Kimber S, et al. Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nat Commun. 2018;9:3707.

Gutiérrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, Rivas JD, Ticona FV, et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia. 2010;24:629–37.

Article  PubMed  Google Scholar 

Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hanamura I, Huang Y, Zhan F, Barlogie B, Shaughnessy J. Prognostic value of cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations. Leukemia. 2006;20:1288–90.

Article  CAS  PubMed  Google Scholar 

López-Corral L, Corchete LA, Sarasquete ME, Mateos MV, García-Sanz R, Fermiñán E, et al. Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies. Haematologica. 2014;99:1365–72.

Article  PubMed  PubMed Central  Google Scholar